Ocular Therapeutix, Inc.

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel